Research Analysts Offer Predictions for VERA Q2 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – HC Wainwright issued their Q2 2025 EPS estimates for Vera Therapeutics in a research note issued to investors on Monday, May 5th. HC Wainwright analyst A. He forecasts that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright currently has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ FY2025 earnings at ($3.18) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $3.30 EPS and FY2029 earnings at $5.37 EPS.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the prior year, the firm earned ($0.56) EPS.

Other equities analysts also recently issued research reports about the stock. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Cantor Fitzgerald dropped their price objective on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday. JPMorgan Chase & Co. decreased their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research note on Tuesday, March 4th. Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective on the stock. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $63.80.

Vera Therapeutics Stock Down 1.2 %

Shares of Vera Therapeutics stock opened at $21.77 on Thursday. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a market capitalization of $1.39 billion, a P/E ratio of -8.34 and a beta of 1.28. The company has a 50 day moving average of $24.22 and a 200 day moving average of $34.72.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Huntington National Bank purchased a new position in shares of Vera Therapeutics in the 4th quarter valued at about $26,000. AlphaQuest LLC purchased a new position in Vera Therapeutics in the fourth quarter valued at about $34,000. GF Fund Management CO. LTD. acquired a new stake in shares of Vera Therapeutics during the 4th quarter valued at approximately $56,000. KBC Group NV boosted its stake in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. Finally, Summit Investment Advisors Inc. grew its holdings in shares of Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after acquiring an additional 639 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.